GlassScriptPhysician profile
David Dennis
NPI 1740711811
$5,766.30
in general payments reported to CMS, 2019-2025
19 companies · $1,329 in 2025
The $1,329 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $103 · 2024: $4,334 · 2025: $1,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,668 · Food and Beverage: $2,161 · Travel and Lodging: $937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,668.13 |
| Food and Beverage | $2,161.35 |
| Travel and Lodging | $936.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,504.81 | 2024 | |
| Genzyme Corporation | $512.19 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $416.63 | 2024-2025 | Dupixent |
| United Therapeutics Corporation | $296.02 | 2024-2025 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $222.48 | 2024-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $183.22 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $123.08 | 2023-2025 | Glassia |
| Inspire Medical Systems, INC. | $119.18 | 2024-2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Insmed, INC. | $54.61 | 2024-2025 | Arikayce, Brinsupri |
| Amgen INC. | $50.08 | 2023-2025 | Tezspire |
| Verona Pharma, INC. | $46.00 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $38.53 | 2025 | Yupelri |
| Fisher & Paykel Healthcare INC | $28.51 | 2025 | Fisher & Paykel Healthcare |
| Pulmonx Corporation | $25.71 | 2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $18.90 | 2025 | |
| Lilly USA, LLC | $17.11 | 2025 | Zepbound, Mounjaro |
| Mylan Specialty L.P. | $16.18 | 2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.07 | 2024 | Ofev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dennis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.